BRD4/NAMPT-IN-1
BRD4/NAMPT-IN-1 (Compound A2) shows strong inhibitory effects on NAMPT and BRD4 (IC50=35 nM (NAMPT) and 58 nM (BRD4) ) . BRD4/NAMPT-IN-1 inhibits the growth and migration of hepatocellular carcinoma cells and promotes apoptosis. BRD4/NAMPT-IN-1 also shows potent anticancer effects in HCCLM3 xenograft mouse model, with no obvious toxic effects[1].
Product Specifications
CAS Number
[3049218-28-9]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Epigenetic Reader Domain; NAMPT
Type
Reference compound
Related Pathways
Epigenetics; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/brd4-nampt-in-1.html
Purity
99.45
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
ClC(C=C1)=CC=C1C2=N[C@@H](CC(NCCCNC(/C=C/C3=CN=CC=C3)=O)=O)C4=NN=C(C)N4C5=C2C(C)=C(C)S5
Molecular Formula
C30H30ClN7O2S
Molecular Weight
588.12
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
BRD4
Available Sizes
Explore Other Products
Browse additional items from our catalog
Nkx3 (Nkx3-2) (NM_007524) Mouse Tagged Lenti ORF Clone
Alpha Synuclein (Alpha Synuclein, Non-A Beta Component Of AD Amyloid, Non-A4 Component Of Amyloid Precursor, NACP, SNCA, PARK1, PARK 1, AlphaSYN, PARK 4, PARK4, Parkinson Disease Familial 1, Parkinson Disease (Autosomal Dominant, Lewy body) 4, SYN)